Synapse - Gynecologic Medicine Service

Results (2180)

Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial

Meeting Abstract

Aghajanian, C.; Schmalfeldt, B.; Okamoto, A.; Reuss, A.; Kim, J. W.; Marquina Ospina, G.; Ayhan, A.; Salutari, V.; Lebreton, C.; Labudovic, D.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors

Meeting Abstract

Ray-Coquard, I. L.; Liu, J. F.; O'Malley, D.; Oaknin, A.; Pothuri, B.; Lorusso, D.; Eskander, R. N.; Westin, S.; Lakhani, N. J.; McKean, W. B.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Global, phase Ib dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced (a) endometrial cancer (EC) that progressed on platinum-based chemotherapy (CTx) and an anti-PD-(L)1 immunotherapy (IO)

Meeting Abstract

Lee, J. Y.; Hasegawa, K.; Kim, B. G.; Corr, B. R.; Kondo, S.; Suzuki, S.; Yunokawa, M.; Miller, D. S.; Tamai, T.; Dutta, L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)

Meeting Abstract

Lee, J. M.; MacLaughlan, S.; Matei, D.; Song, M.; Brubaker, L.; Rimmel, B.; Eskander, R. N.; Kyi, C.; Williams, H.; Duska, L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

Meeting Abstract

Friedman, C.; De Burgh Williams, A.; Lopez, J. S.; Ouali, K.; Middleton, M. R.; Thistlethwaite, F.; Hamid, O.; Izar, B.; Moreno Garcia, V.; Johnson, M. L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study

Meeting Abstract

Danska-Bidzinska, A.; Makker, V.; Salutari, V.; Ayhan, A.; Romero, I.; Levy, T.; McCormack, M.; Baurain, J. F.; Mach, P.; Cadoo, K. A.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation

Meeting Abstract

Schram, A. M.; Lopes, G.; El-Khoueiry, A. B.; Fontana, E.; Karasic, T. B.; Kummar, S.; Lorusso, P.; Gregorc, V.; Millward, M.; Aix, S. P.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors

Meeting Abstract

Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation

Meeting Abstract

Guo, R.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S.; Calvo, E.; Sonpavde, G. P.; Awad, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012

Meeting Abstract

González-Martín, A.; Pothuri, B.; Ginesta, M. P. B.; Graybill, W. S.; Vergote, I. B.; McCormick, C.; Mirza, M. R.; Moore, R. G.; Lorusso, D.; O'Cearbhaill, R. E.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save